| 1 |
Smith JB, Herbert JJ, Truong NR, Cunningham AL. Cytokines and chemokines: The vital role they play in herpes simplex virus mucosal immunology. Front Immunol 2022;13:936235. [DOI: 10.3389/fimmu.2022.936235] [Reference Citation Analysis]
|
| 2 |
Carr DJJ, Berube A, Gershburg E. The Durability of Vaccine Efficacy against Ocular HSV-1 Infection Using ICP0 Mutants 0∆NLS and 0∆RING Is Lost over Time. Pathogens 2021;10. [PMID: 34832625 DOI: 10.3390/pathogens10111470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Filiberti A, Gmyrek GB, Berube AN, Royer DJ, Carr DJJ. An intact complement system dampens cornea inflammation during acute primary HSV-1 infection. Sci Rep 2021;11:10247. [PMID: 33986436 DOI: 10.1038/s41598-021-89818-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Carr DJJ, Berube AN, Filiberti A, Gmyrek GB. Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0ΔNLS vaccine against ocular HSV-1 challenge. Vaccine 2021;39:2526-36. [PMID: 33814229 DOI: 10.1016/j.vaccine.2021.03.075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 5 |
Carr DJJ, Gmyrek GB, Filiberti A, Berube AN, Browne WP, Gudgel BM, Sjoelund VH. Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins. Immunohorizons 2020;4:608-26. [PMID: 33037098 DOI: 10.4049/immunohorizons.2000060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 6 |
Ramsey NLM, Visciano M, Hunte R, Loh LN, Burn Aschner C, Jacobs WR Jr, Herold BC. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus. J Virol 2020;94:e00335-20. [PMID: 32295919 DOI: 10.1128/JVI.00335-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 7 |
Royer DJ, Montgomery ML, Carr DJ. Mucosal Regulatory System for Balanced Ocular Immunity. Mucosal Vaccines 2020. [DOI: 10.1016/b978-0-12-811924-2.00017-1] [Reference Citation Analysis]
|
| 8 |
Poccardi N, Rousseau A, Haigh O, Takissian J, Naas T, Deback C, Trouillaud L, Issa M, Roubille S, Juillard F, Efstathiou S, Lomonte P, Labetoulle M. Herpes Simplex Virus 1 Replication, Ocular Disease, and Reactivations from Latency Are Restricted Unilaterally after Inoculation of Virus into the Lip. J Virol 2019;93:e01586-19. [PMID: 31554680 DOI: 10.1128/JVI.01586-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Royer DJ, Echegaray-Mendez J, Lin L, Gmyrek GB, Mathew R, Saban DR, Perez VL, Carr DJ. Complement and CD4+ T cells drive context-specific corneal sensory neuropathy. Elife 2019;8:e48378. [PMID: 31414985 DOI: 10.7554/eLife.48378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 10 |
Royer DJ, Hendrix JF, Larabee CM, Reagan AM, Sjoelund VH, Robertson DM, Carr DJJ. Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection. Mucosal Immunol 2019;12:827-39. [PMID: 30670763 DOI: 10.1038/s41385-019-0131-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 11 |
Jiao H, Hill LJ, Downie LE, Chinnery HR. Anterior segment optical coherence tomography: its application in clinical practice and experimental models of disease. Clin Exp Optom 2019;102:208-17. [PMID: 30270476 DOI: 10.1111/cxo.12835] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 12 |
Royer DJ, Elliott MH, Le YZ, Carr DJJ. Corneal Epithelial Cells Exhibit Myeloid Characteristics and Present Antigen via MHC Class II. Invest Ophthalmol Vis Sci 2018;59:1512-22. [PMID: 29625473 DOI: 10.1167/iovs.17-23279] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 13 |
Rider PJF, Musarrat F, Nabil R, Naidu S, Kousoulas KG. First Impressions-the Potential of Altering Initial Host-Virus Interactions for Rational Design of Herpesvirus Vaccine Vectors. Curr Clin Microbiol Rep 2018;5:55-65. [PMID: 30560044 DOI: 10.1007/s40588-018-0082-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 14 |
Royer DJ, Carr DJJ. Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?". J Virol 2017;91:e01464-17. [PMID: 29138328 DOI: 10.1128/JVI.01464-17] [Reference Citation Analysis]
|
| 15 |
Ghiasi H. Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth? J Virol 2017;91:e01421-17. [PMID: 29138327 DOI: 10.1128/JVI.01421-17] [Reference Citation Analysis]
|
| 16 |
Lee DH, Ghiasi H. Reply to "Herpes Simplex Virus 1, Macrophages, and the Cornea". J Virol 2017;91:e01317-17. [PMID: 29030535 DOI: 10.1128/JVI.01317-17] [Reference Citation Analysis]
|
